Drug Studies in the Elderly

Methodological Concerns

  • Neal R. Cutler
  • Prem K. Narang

Table of contents

  1. Front Matter
    Pages i-xxv
  2. Research Determinants in Aging

    1. Front Matter
      Pages 1-1
    2. Thomas M. Vogt
      Pages 3-27
    3. Prem K. Narang
      Pages 29-48
    4. Alexander M. M. Shepherd
      Pages 49-67
    5. William B. Ershler, Marc E. Weksler
      Pages 69-79
    6. Brian F. Johnson, Janice C. Hitzhusen
      Pages 81-99
    7. Cho-Ming Loi, Robert E. Vestal
      Pages 101-121
    8. Elizabeth J. Read, Harvey G. Klein
      Pages 123-150
    9. Neal R. Cutler
      Pages 151-164
  3. Pharmacokinetics and Pharmacodynamics in the Elderly

    1. Front Matter
      Pages 165-165
    2. Matthew V. Rudorfer, William Z. Potter
      Pages 167-187
    3. David S. Roffman, Alan Forrest
      Pages 249-272
    4. William H. Theodore
      Pages 273-282
    5. Donald B. Calne, Arto Laihinen
      Pages 299-311
    6. Neal R. Cutler, Prem K. Narang
      Pages 313-332
  4. General Perspectives

    1. Front Matter
      Pages 333-333
    2. R. Gary Hollenbeck, Peter P. Lamy
      Pages 335-353
    3. William B. Abrams, Bruce E. Rodda
      Pages 355-368
    4. Paul Leber
      Pages 369-379
    5. David G. Covell, Prem K. Narang
      Pages 381-405
    6. Lawrence J. Lesko
      Pages 407-416
    7. Barbara R. Heller, Maureen E. Power, Georgeanne Cox Santolla
      Pages 417-428
  5. Back Matter
    Pages 429-438

About this book


Clinical trials are the most definitive tool for evaluation of the applica­ bility of clinical investigations. The main objective of clinical investiga­ tions is to assess the potential value of a therapeutic entity in the treat­ ment or prophylaxis of a disease or a condition. It is also deemed necessary at this stage to obtain information regarding the undesirable side effects, associated risks, and their interrelationship with clinical assessments. Most of these clinical investigations conform, in some form or fashion, to the guidelines adopted by the Food and Drug Administration (FDA) for a given class of compounds. Clinical investigations in the past have not included specific studies in special or subpopulations, e.g., the elderly. Because of an ever-increasing elderly population, newer policies for clinical investigations are now being debated with the recognition of enhanced drug sensitivity in this special population. This key research activity can lead not only to improved health care in the elderly but also to control of its costs.


Alzheimer Assessment Thymus Transplantation age dementia dopamine

Editors and affiliations

  • Neal R. Cutler
    • 1
  • Prem K. Narang
    • 2
  1. 1.Department of Geriatrics Cedars-Sinai Medical CenterUniversity of California-Los Angeles School of MedicineLos AngelesUSA
  2. 2.Clinical Pharmacokinetics Research Laboratory Pharmacy Department Clinical CenterNational Institutes of HealthBethesdaUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Internal Medicine & Dermatology